Palbociclib-d8

• UNSPSC Description:

  Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

• Target Antigen:

  CDK

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.84

• Solubility:

  DMSO : 1 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 8.33 mg/mL (ultrasonic;warming;adjust pH to 3 with HCl;heat to 80°C)

• Smiles:

  O=C1N(C2=NC(NC3=NC=C(C=C3)N4C([2H])(C([2H])(NC([2H])(C4([2H])[2H])[2H])[2H])[2H])=NC=C2C(C)=C1C(C)=O)C5CCCC5

• Molecular Weight:

  455.58

• References & Citations:

  [1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1628752-83-9